Clinical Improvement and Prolonged Survival With High Dose Intrathecal Methotrexate for Carcinomatous Meningitis Secondary to a Lung Adenocarcinoma

Florian Clatot; Philippe David; Sophie Laberge-Le-Couteulx; Emmanuel Blot

doi:10.4021/wjon358w

Clinical Improvement and Prolonged Survival With High Dose Intrathecal Methotrexate for Carcinomatous Meningitis Secondary to a Lung Adenocarcinoma

World J Oncol. 2011 Oct;2(5):262-264. doi: 10.4021/wjon358w. Epub 2011 Oct 28.

Authors

Florian Clatot¹, Philippe David², Sophie Laberge-Le-Couteulx³, Emmanuel Blot⁴

Affiliations

¹ Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.
² Department of Pneumology, CHI Les Feugrais, Elbeuf, France.
³ Department of Pathology, Centre Henri Becquerel, Rouen, France.
⁴ Department of Medical Oncology, Centre Saint Yves and CH Bretagne Atlantique, Vannes, France.

Abstract

Carcinomatous meningitis (CM) is a devastating complication of advanced cancers. No standard treatment is available for CM secondary to solid tumors. In particular, very few data have been published for CM related to lung adenocarcinoma. Herein we report the case of a 39-year old woman treated for a metastatic lung adenocarcinoma, without EGFR mutation, complicated by a CM. Intrathecal administrations of high dose methotrexate produced both a clinical improvement of symptoms related to CM and an unusually delayed survival.

Keywords: Carcinomatous meningitis; Intrathecal; Leptomeningeal metastasis; Lung adenocarcinoma; Methotrexate.

Publication types

Case Reports